title: Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function?
abstract: Poor left ventricular function is a predictor of sudden death. Both antiarrhythmic drugs and implantable cardioverter-defibrillators (ICDs) promise to reduce the sudden death rate in these patients and consequently improve survival. In patients without spontaneous ventricular tachyarrhythmias, only beta-blocking agents and amiodarone have been shown to reduce sudden death and improve survival in some studies, whereas class I antiarrhythmic drugs increased mortality. For patients with documented ventricular tachyarrhythmias, protection against sudden death by serially tested class I antiarrhythmic drugs is at best moderate. There is some evidence suggesting that therapy with class III antiarrhythmic drugs, either amiodarone or dl-sotalol, may reduce sudden death rates and improve overall mortality in comparison to therapy with class I antiarrhythmic drugs. ICDs have been shown to prevent sudden death reliably. In published patient cohorts in which only patients who were not inducible off antiarrhythmic drugs or still inducible on antiarrhythmic drugs received an ICD, the ICD seemed to improve overall survival in comparison to class I antiarrhythmic drugs. A small prospective randomized study that compared a conventional therapy strategy to primary ICD implantations showed an improved outcome with ICDs as therapy of first choice. However, these studies included many patients treated with class I antiarrhythmic drugs considered to be less effective. In matched control studies comparing the ICD to amiodarone or dl-sotalol, less sudden deaths and an improved overall survival could be shown for the ICD in general without stratification for left ventricular function. Thus, in patients with hemodynamically nontolerated ventricular tachyarrhythmias, the ICD seems to improve survival in comparison to class I antiarrhythmic drugs, dl-sotalol, or amiodarone. However, in patients with poor left ventricular function, therapy with ICDs seems to be less cost-effective than in patients with preserved left ventricular function. In patients with very poor left ventricular function who are evaluated for cardiac transplantation, the ICD seems to change only the mode of death from sudden to a nonsudden cardiac death if transplantation cannot be performed soon.
authors.affiliation: Hospital of the Westfälische Wilhelms-University of Münster, Department of Cardiology/Angiology, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Block
authors.forename: D
authors.initials: D
authors.lastname: Hammel
authors.forename: D
authors.initials: D
authors.lastname: Böcker
authors.forename: M
authors.initials: M
authors.lastname: Borggrefe
authors.forename: G
authors.initials: G
authors.lastname: Breithardt
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D017147:Defibrillators, Implantable; D006801:Humans; D017180:Tachycardia, Ventricular / Q000150:complications / Q000628:therapy*; D018487:Ventricular Dysfunction, Left / Q000150:complications*
chemical_list: D000889:Anti-Arrhythmia Agents